RESUMEN
Spasmolytic polypeptide (SP/TFF2)-expressing metaplasia (SPEM) is induced by oxyntic atrophy and is known as a precancerous or paracancerous lesion. We seek to determine whether the gastrin receptor or H(2) histamine receptor influence the development of SPEM. DMP-777 was administered to gastrin receptor and/or H(2) receptor-deficient mice and wild-type mice. Gastric mucosal lineage changes were analyzed. The mucosa from double knockout mice and H(2) receptor knockout mice contained elevated numbers of dual TFF2 and intrinsic factor immunoreactive cells even before DMP-777 treatment. All genotypes of mice showed SPEM after 7-day treatment. In all types of knockout mice, the number of TFF2 immunoreactive cells remained elevated after cessation of treatment. The H(2) receptor and gastrin receptor do not affect emergence of SPEM. However, it is suggested that the absence of H(2) receptor signaling causes a delay in the maturation of chief cells from mucous neck cells.
Asunto(s)
Linaje de la Célula , Mucosa Gástrica/citología , Células Parietales Gástricas/patología , Receptor de Colecistoquinina B/metabolismo , Receptores Histamínicos H2/metabolismo , Animales , Atrofia/inducido químicamente , Atrofia/patología , Azetidinas/efectos adversos , Azetidinas/farmacología , Diferenciación Celular/efectos de los fármacos , Linaje de la Célula/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Mucosa Gástrica/metabolismo , Gastrinas/sangre , Factor Intrinseco/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Mucinas/metabolismo , Proteínas Musculares/metabolismo , Células Parietales Gástricas/metabolismo , Péptidos/metabolismo , Piperazinas/efectos adversos , Piperazinas/farmacología , Receptor de Colecistoquinina B/genética , Receptores Histamínicos H2/genética , Factor Trefoil-2RESUMEN
A 70-year-old woman suffering from HCV-related liver cirrhosis was admitted for abnormal bleeding. Laboratory findings included PT at 46.6 sec, APTT at >212 sec, factor V activity of <3%, and factor V inhibitor of 2 BU. Having experienced a persistent bleeding tendency for one month, the patient was started on prednisolone (0.8 mg/kg/day). Within a few days, the inhibitor became undetectable and clinical bleeding disappeared. Although clinical improvement was achieved, she died 6 months after the initial bleeding episode from the progression of a lung cancer. An autopsy revealed squamous cell carcinoma of the lung and hepatocellular carcinoma.
